Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro ...
Direct oral anticoagulants (DOACs) are now an option in the prevention and treatment of venous thromboembolic events (VTE) in patients with active cancer. Pharmacokinetics of DOACs are …
Venous thromboembolic events with vascular endothelial growth …
Jul 1, 2013 · Several multitargeted vascular endothelial growth factor receptor (VEGFR) tyrosine-kinase inhibitors (TKI) agents have been approved including sunitinib, sorafenib, pazopanib, …
Risk factors for venous thromboembolism (VTE) among patients …
May 31, 2023 · We examined the incidence of VTE, a common adverse event (AE) among pts with lung cancer, for those receiving ami monotherapy, laz monotherapy, and ami+laz to …
Early onset venous and arterial thrombosis when combining …
Mar 1, 2025 · Management of acute VTE on therapy (including TKI or amivantamab) in lung cancer follows established guidelines such as those from ASCO (Key et al., 2023); initial 6 …
Thromboembolic Events Associated with Epidermal Growth Factor …
Feb 20, 2024 · We affirm the concerns regarding the risk of thromboembolic AEs, especially VTE when EGFR-TKIs are used in patients with cancer. Consistent with existing literature, the most …
抗血管生成靶向药物与出血及血栓栓塞 - MedSci
目前已有多种类型的VEGF通路抑制剂，包括针对VEGF或VEGFR的中和抗体、VEGFR-酪氨酸激酶抑制剂（TKI）等已被批准用于肿瘤临床治疗或正进行不同阶段临床试验（见表1）。 他们 …
血栓事件对ALK-TKI的疗效有何影响？ - 网易
Nov 17, 2024 · 本研究首次通过全基因组关联分析（GWAS），探索了与ALK、ROS1融合阳性NSCLC患者VTE和ATE相关的临床人口统计学因素及胚系遗传因素。 该研究为一项前瞻性队 …
Management of venous thromboembolism in patients with lung …
Venous thromboembolism (VTE) is common and life-threatening in patients with lung cancer. Management of VTE is critical for patients with lung cancer. Risk assessment, …
Venous thromboembolic events with vascular endothelial growth …
A trial-level meta-analysis was conducted to determine the relative risk (RR) of venous thromboembolic events (VTEs) associated with approved vascular endothelial growth factor …
Retrospective Study of Bleeding Risk with Concomitant Vascular ...
The current study showed that use of concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI) and therapeutic anticoagulation was associated with an …